Back to top
more

Intuitive Surgical (ISRG)

(Delayed Data from NSDQ)

$471.85 USD

471.85
1,399,486

+1.77 (0.38%)

Updated Aug 11, 2025 04:00 PM ET

After-Market: $471.75 -0.10 (-0.02%) 6:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (148 out of 244)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sweta Jaiswal headshot

3 MedTech Stocks for Safe Returns as Hurricane Fears Peak

by Sweta Jaiswal

With the hurricane season at the peak, we bring three safe picks for investors.

    Zacks Equity Research

    Cerner's CommunityWorks Picked by Reeves County Hospital

    by Zacks Equity Research

    Cerner (CERN) sees a slew of developments in its EHR platform, market prospects bright.

      Zacks Equity Research

      Here's Why You Should Hold Becton, Dickinson (BDX) Stock Now

      by Zacks Equity Research

      Becton, Dickinson (BD) is likely to gain from expansion into emerging overseas markets.

        Zacks Equity Research

        Abbott Banks on New Approvals and Buyouts, Competition Rife

        by Zacks Equity Research

        Abbott's (ABT) receipt of FDA approval for XIENCE Sierra coronary stent system as well as a reimbursement approval in Japan for the same device will help it revive the dull Vascular business.

          Zacks Equity Research

          Cardiovascular Systems Stealth 360 Peripheral OAS Goes Global

          by Zacks Equity Research

          Following the recent extension of its partnership with OrbusNeich, Cardiovascular Systems' (CSII) Stealth 360 Peripheral OAS is put to first commercial use in Hong Kong.

            Zacks Equity Research

            Cerner Integrated Platform Implemented by Spectrum Health

            by Zacks Equity Research

            Spectrum Health selects Cerner's (CERN) Cerner Integrated Platform to treat psychological disorders.

              Zacks Equity Research

              Insulet Advances on Omnipod Reimbursement Update, Runs Risks

              by Zacks Equity Research

              Insulet (PODD) commences 2018 with favorable reimbursement updates. The company attains several landmarks regarding Omnipod's market reach.

                Zacks Equity Research

                Here's Why You Should Hold on to Align Technology (ALGN) Now

                by Zacks Equity Research

                Continued strength in Align Technology's (ALGN) Invisalign volumes impresses. Overdependence on Invisalign Technology system is a concern.

                  Zacks Equity Research

                  Here's Why You Should Hold AngioDynamics' (ANGO) Stock Now

                  by Zacks Equity Research

                  AngioDynamics (ANGO) to benefit from a solid product portfolio. However, the company???s core Peripheral Vascular business has been sluggish.

                    Zacks Equity Research

                    Veeva's Vault CDMS to Unify Clinical Data in Single Platform

                    by Zacks Equity Research

                    Veeva's (VEEV) cloud-based applications' market prospects bright.

                      Zacks Equity Research

                      Here's Why You Should Invest in Masimo (MASI) Right Now

                      by Zacks Equity Research

                      A raised guidance for 2018 and positive developments make Masimo (MASI) a lucrative choice for investors.

                        Zacks Equity Research

                        ResMed Unveils AirFit F30, Expands AirFit Mask Portfolio

                        by Zacks Equity Research

                        ResMed's (RMD) recent product launches will strengthen its position in the high-potential sleep-disordered breathing market.

                          Zacks Equity Research

                          QIAGEN (QGEN) Partners DiaSorin to Extend QuantFERON Offers

                          by Zacks Equity Research

                          Per QIAGEN (QGEN), the latest LIAISON QuantiFERON-TB Plus Test is likely to tackle the growing transformation of global latent TB testing market into the modern blood-based QuantiFERON technology.

                            Zacks Equity Research

                            Cooper's MiSight Lens Effective in Checking Juvenile Myopia

                            by Zacks Equity Research

                            Cooper's (COO) core CVI business gets a boost from MiSight's positive study results.

                              Zacks Equity Research

                              Can Intuitive Surgical (ISRG) Keep the Earnings Surprise Streak Alive?

                              by Zacks Equity Research

                              Intuitive Surgical (ISRG) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

                                Zacks Equity Research

                                Here's Why You Should Add Abbott (ABT) to Your Portfolio Now

                                by Zacks Equity Research

                                Abbott (ABT) continues to deliver strong and consistent performance in all segments. The company has also been hogging the limelight within Diabetic Care on progress with its FreeStyle Libre.

                                  Zacks Equity Research

                                  CVS Health (CVS) PBM Strengthens, Aetna Deal Shows Promise

                                  by Zacks Equity Research

                                  A robust 2019 PBM selling season is a tailwind for CVS Health (CVS). Additionally, the company's milestone acquisition of Aetna might alter the whole healthcare landscape in the United States.

                                    Zacks Equity Research

                                    QIAGEN Collaborates With NeuMoDx, Expands NGS Portfolio

                                    by Zacks Equity Research

                                    QIAGEN (QGEN) forges ahead with deals to strengthen the NGS Platform.

                                      Zacks Equity Research

                                      DaVita Kidney Care Opens 150000-Square-Foot Campus in DeLand

                                      by Zacks Equity Research

                                      DaVita's (DVA) dialysis care in the United States gets a boost; market prospects solid.

                                        Zacks Equity Research

                                        Omnicell Continues to Pursue Buyouts, Costs on the Rise

                                        by Zacks Equity Research

                                        Omnicell (OMCL) progresses well with its strategy to grow inorganically. Rising operating expenses a concern.

                                          Zacks Equity Research

                                          Cardiovascular Systems Portfolio Strong, Competition Rife

                                          by Zacks Equity Research

                                          Cardiovascular Systems (CSII) suffers a long history of net loss since its launch in 1989 with no immediate solution in sight.

                                            Zacks Equity Research

                                            Pacific Biosciences (PACB) Up as VGP Picks Flagship Sequel

                                            by Zacks Equity Research

                                            Pacific Biosciences (PACB) sees a slew of developments in its coveted SMRT Sequel platform.

                                              Zacks Equity Research

                                              Veeva Gains as MD&D Companies Pick Its Cloud-Based Services

                                              by Zacks Equity Research

                                              Veeva's (VEEV) focus on cloud-based services is likely to open up substantial opportunities for the company.

                                                Zacks Equity Research

                                                Pacific Biosciences (PACB) Jumps: Stock Rises 5.4%

                                                by Zacks Equity Research

                                                Pacific Biosciences (PACB) was a big mover last session, as the company saw its shares rise more than 5% on the day amid huge volumes.

                                                  Zacks Equity Research

                                                  Here's Why You Should Invest in Penumbra (PEN) Stock Now

                                                  by Zacks Equity Research

                                                  The market is quite upbeat about Penumbra's (PEN) recently-closed buyout of a controlling stake in MVI Health, aimed at capturing the great potential of virtual reality application.